We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Portable Immunoassay System Advances Toward Point-of-Care Biomarker Testing

By LabMedica International staff writers
Posted on 10 Jun 2026

Proxim Diagnostics Corp. More...

(Santa Clara, CA, USA) has announced that its Profile System, a handheld point-of-care immunoassay platform, has completed development. The milestone includes completion of the reader, single-use cartridge, and initial manufacturing capability. The fully automated, portable system is designed to deliver high-sensitivity biomarker testing at the point of care and is now positioned for production readiness and potential partnerships in acute care and research applications.

The technology integrates a disposable cartridge with a compact reader to execute immunoassays intended to deliver centralized laboratory performance closer to the bedside. The Profile System is designed as a flexible architecture capable of supporting multiple assay types on the same handheld reader. The company indicates this may enable a broad test menu over time, including research‑use‑only (RUO) assays for biopharma customers and future clinical assays that would be subject to applicable regulatory requirements.

Proxim is advancing applications in acute care biomarkers, including cardiac and inflammatory markers where rapid point‑of‑care results can support time‑critical decisions. The platform has demonstrated key analytical traits associated with high‑sensitivity troponin testing. In testing of its high‑sensitivity troponin I assay, the system achieved an 81% detectable rate in the normal population.

The company also highlights RUO assays for cytokines such as interleukin‑6, interferon‑gamma, and CXCL9 for inpatient and outpatient use by biopharma clients developing T‑cell engager therapies, where rapid cytokine measurements may support prediction, monitoring, and management of cytokine release syndrome (CRS), immune effector cell‑associated neurotoxicity syndrome (ICANS), hemophagocytic lymphohistiocytosis (HLH), and other immuno‑oncology therapy‑related adverse effects.

“Completing development of our handheld reader, cartridge, and initial manufacturing capacity is a major milestone for Proxim. We now have a fully developed product platform that is ready to support high-value clinical and RUO opportunities,” said Mikhail Briman, Ph.D., CEO and co-founder of Proxim Diagnostics.

“Our goal has always been to bring the sensitivity and precision of centralized laboratory testing into a portable point-of-care format, and this achievement puts us in a strong position to engage strategic partners and customers across biopharma, acute care, women’s health, and other important clinical and research areas,” added Briman.

Related Links
Proxim Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Platelet Function Analyzer
PL-12
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Dr. Olivia Belbin, head of the Molecular Neurodegeneration Group at IR Sant Pau and study corresponding author, with Alba Cervantes (right), first author and IR Sant Pau researcher (Photo courtesy of IR Sant Pau)

Blood Biomarker Detects Alzheimer’s Changes Decades Before Symptoms in Down Syndrome

Alzheimer’s disease can begin altering the brain long before clinical symptoms appear, creating a challenge for early-stage detection and research. People with Down syndrome face a particularly high age-related... Read more

Molecular Diagnostics

view channel
Photo courtesy of National Human Genome Research Institute

Genomic Screening Expands Detection of Treatable Conditions in Newborns

Conventional newborn screening can miss conditions that lack biochemical biomarkers or present atypically. Initial hearing screens may also fail to detect hearing loss that is later identified through... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: NMPA approvals for Quanterix HD-X and SR-X instruments and four neurology biomarker assays expand access to ultrasensitive blood-based testing in China (Photo courtesy of Quanterix Corporation)

Regulatory Milestone Expands Access to Blood-Based Neurology Biomarker Testing in China

Quanterix Corporation (Billerica, MA, USA) and Innovita Biological Technology Co., Ltd. (Beijing, China) announced regulatory approvals that expand access to Quanterix SIMOA technology and neurology biomarker... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.